Metastatic Melanoma Drugs Market By Therapy Type (Immunotherapy {PD-1/PD-L1 Inhibitors, CTLA-4 Inhibitors}, Targeted Therapy {BRAF Inhibitors, MEK Inhibitors}, Chemotherapy, Combination Therapy), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-user (Hospitals, Specialty Clinics, Homecare Settings), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Report Coverage:

By Therapy Type

• Immunotherapy
  • PD-1/PD-L1 Inhibitors
  • CTLA-4 Inhibitors
• Targeted Therapy
  • BRAF Inhibitors
  • MEK Inhibitors
• Chemotherapy
• Combination Therapy

 By Route of Administration

• Oral
• Injectable

 By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

 By End-user

• Hospitals
• Specialty Clinics
• Homecare Settings

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Bristol Myers Squibb Company
• Merck & Co., Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Amgen, Inc.
• AstraZeneca plc
• Pfizer Inc.
• Sanofi
• Regeneron Pharmaceuticals Inc.
• GSK plc. 
• Eli Lilly and Company
• Incyte.
•  Exelixis, Inc.
• BeiGene Ltd
• Immunocore Holdings plc
• IOVANCE Biotherapeutics, Inc.
• Nektar
• Adaptimmune